Milligan to step down as head of Gilead Sciences
Gilead Sciences president and CEO John Milligan will step down after a 28-year career with the company. Milligan will remain in his current position through the end of the year, while the board of directors conducts a search to identify a successor, the company said.
“It has been an honor to work at Gilead for my entire professional career and, now that the company is on solid footing for the future, the board and I have agreed it is a good time to turn the reins over to a new leader,” Milligan said. “I’m looking forward to a well-deserved break and will then move on to new and different opportunities.”
“Today, Gilead has the right strategy in place to successfully execute on its mission of improving the lives of people with some of the world’s most serious diseases, led by a robust HIV franchise, an industry-leading cell therapy platform and a late-stage pipeline in NASH and inflammation,” John Martin, Gilead chairman of the board of directors, said.
“Moreover, we have the resources to continue investing in and expanding our strong [research and development] pipeline, which remains paramount to our success,” Martin said. “We are excited about our growth potential, and intend to hire a CEO who will build on the foundation that John Milligan has put in place, and execute on our ambitious goals for the future.”
“On behalf of the entire board, I want to thank John Milligan for his countless contributions to Gilead over nearly 30 years, and commend him for operating throughout his career with the highest personal and professional integrity,” said Gilead Sciences board of directors lead independent director John Cogan. “Given his long-standing dedication to Gilead, it is no surprise that John is committed to facilitating a seamless transition for all of our stakeholders, as we work to identify his successor.”
Milligan also will step down from the Gilead board of directors at the end of the year. Additionally, Martin has announced his intent to step down from the board at the time a new CEO joins the company, having determined that this would be a natural transition point from his successive roles as CEO, executive chairman and chairman.
“It has been an honor to work at Gilead for my entire professional career and, now that the company is on solid footing for the future, the board and I have agreed it is a good time to turn the reins over to a new leader,” Milligan said. “I’m looking forward to a well-deserved break and will then move on to new and different opportunities.”
“Today, Gilead has the right strategy in place to successfully execute on its mission of improving the lives of people with some of the world’s most serious diseases, led by a robust HIV franchise, an industry-leading cell therapy platform and a late-stage pipeline in NASH and inflammation,” John Martin, Gilead chairman of the board of directors, said.
“Moreover, we have the resources to continue investing in and expanding our strong [research and development] pipeline, which remains paramount to our success,” Martin said. “We are excited about our growth potential, and intend to hire a CEO who will build on the foundation that John Milligan has put in place, and execute on our ambitious goals for the future.”
“On behalf of the entire board, I want to thank John Milligan for his countless contributions to Gilead over nearly 30 years, and commend him for operating throughout his career with the highest personal and professional integrity,” said Gilead Sciences board of directors lead independent director John Cogan. “Given his long-standing dedication to Gilead, it is no surprise that John is committed to facilitating a seamless transition for all of our stakeholders, as we work to identify his successor.”
Milligan also will step down from the Gilead board of directors at the end of the year. Additionally, Martin has announced his intent to step down from the board at the time a new CEO joins the company, having determined that this would be a natural transition point from his successive roles as CEO, executive chairman and chairman.